Cited by 355Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular HealthParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 226 of the 228 references it cites were found in a registry or an index.

HDL-targeted therapies: progress, failures and future

Kingwell, Bronwyn A., Chapman, M. John, Kontush, Anatol, Miller, Norman E.·2014·Nature Reviews Drug Discovery

Open this paper in CoChat — free account

Abstract

Since the discovery in the 1970s that plasma levels of high-density lipoprotein cholesterol (HDL-C) are inversely associated with cardiovascular outcome, it has been postulated that HDL is anti-atherogenic and that increasing HDL-C levels is a promising therapeutic strategy. However, the recent failure of three orally active, HDL-C-raising agents has introduced considerable controversy, prompting the question of whether increasing the cholesterol cargo of HDL in a non-selective manner is an effective pharmacological approach for the translation of its atheroprotective and vasculoprotective activities. The interrelationships between HDL-C concentration, HDL particle number and levels of diverse HDL particle subpopulations of defined composition are complex, as are their relationships with reverse cholesterol transport and other anti-atherogenic functions. Such complexity highlights the incompleteness of our understanding of the biology of HDL particles. This article examines the HDL hypothesis in molecular and mechanistic terms, focusing on features that have been addressed, those that remain to be tested, and potential new targets for future pharmacological interventions.

Integrity signals

Registry

Crossref · 10.1038/nrd4279

Cites

226 of 226 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.
(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Self-citation
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Self-citation

Show all 228 references

Research works printed but not linked: 3

Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380, 572–580 (2012). This is the first study to test the causality of the relationship between CHD and HDL by genome-wide Mendelian randomization analysis. · DOI · Paper page
Goffinet, M. et al. Anti-atherosclerotic effect of CER-001, an engineered HDL-mimetic, in the high-fat diet-fed LDLr knock-out mouse. Circulation Abstr. 126, A18667 (2012).
Keyserling, C. H. et al. CER-001, a synthetic HDL-mimetic, safely mobilizes cholesterol in healthy dyslipidemic volunteers. Circulation Abstr. 124, A15525 (2011).

Sorted by citations

Items 201–300 of 355

Mango phenolics increase the serum apolipoprotein A1/B ratio in rats fed high cholesterol and sodium cholate diets
Domínguez-Avila, J. A., Astiazarán‐García, H., Wall‐Medrano, A., la Rosa, L. A. D., ́Álvarez-Parrilla, E., & González-Aguilar, G. A. (2018) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.9340 · Cited by 13
Immature surfactant protein-B impairs the antioxidant capacity of HDL
Banfi, C., Brioschi, M., Karjalainen, M. K., Huusko, J. M., Gianazza, E., & Agostoni, P. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.02.057 · Cited by 13
Adenosine-modulating synthetic high-density lipoprotein for chemoimmunotherapy of triple-negative breast cancer
Gong, X., Zheng, C., Cai, Y., Zhang, W., Zhu, B., Rong, R., Kong, Y., Zhang, Y., Wang, J., Li, Y., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.064 · Cited by 12
Peptide-Based HDL as an Effective Delivery System for Lipophilic Drugs to Restrain Atherosclerosis Development
Gao, J., Li, Z., Li, J., Song, P., Yang, J., Xiao, W. L., Li, N., & Xu, R. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s374736 · Cited by 12
High-Density Lipoprotein Infusion Therapy and Atherosclerosis
Chen, N., & Frishman, W. H. (2016) · Cardiology in Review · doi:10.1097/crd.0000000000000111 · Cited by 13
Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity
Cukier, A. M. O., Thérond, P., Didichenko, S. A., Guillas, I., Chapman, M. J., Wright, S. D., & Kontush, A. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.05.010 · Cited by 12
Self-citation
Circulating HDL levels control hypothalamic astrogliosis via apoA-I
Götz, A., Lehti, M., Donelan, E. M., Striese, C., Cucuruz, S., Sachs, S., Yi, C., Woods, S. C., Wright, S. D., Müller, T. D., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.m085456 · Cited by 11
Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity
Gille, A., Duffy, D., Tortorici, M. A., Wright, S. D., Deckelbaum, L. I., & D’Andrea, D. M. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1337 · Cited by 13
Inheritance of high and low HDL: mechanisms and management
Sourlas, A., & Kosmas, C. E. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000610 · Cited by 13
The Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 12
Endothelial Lipase Modulates Paraoxonase 1 Content and Arylesterase Activity of HDL
Schilcher, I., Stadler, J. T., Lechleitner, M., Hrzenjak, A., Berghold, A., Pregartner, G., Lhomme, M., Holzer, M., Korbelius, M., Reichmann, F., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020719 · Cited by 13
Self-citation
Current Trends and Future Perspectives of State-of-the-Art Proteomics Technologies Applied to Cardiovascular Disease Research
Singh, S. A., Aïkawa, E., & Aikawa, M. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0499 · Cited by 12
Lipoprotein modulation of proteinuric renal injury
Tsuchida, Y., Zhong, J., Otsuka, T., Dikalova, A., Pastan, I. H., Anantharamaiah, G. M., Linton, M. F., Yancey, P. G., Ikizler, T. A., Fogo, A. B., et al. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0253-6 · Cited by 11
Effects of cinnamon supplementation on lipid profiles among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis
Wu, T., Huang, W., He, M., & Yue, R. (2022) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2022.101625 · Cited by 11
Integrated omics approach for the identification of HDL structure-function relationships in PCSK9-related familial hypercholesterolemia
Darabi, M., Lhomme, M., Ponnaiah, M., Pučić‐Baković, M., Guillas, I., Frisdal, É., Bittar, R., Croyal, M., Mathéron, L., Poupel, L., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.07.003 · Cited by 11
Self-citation
Klinische Bedeutung des HDL-Cholesterins
März, W., Kleber, M. E., Scharnagl, H., Speer, T., Zewinger, S., Ritsch, A., Parhofer, K. G., von Eckardstein, A., Landmesser, U., & Laufs, U. (2016) · Herz · doi:10.1007/s00059-016-4499-0 · Cited by 11
High-density lipoprotein mimetic nanotherapeutics for cardiovascular and neurodegenerative diseases
Ahn, S. I., Park, H., Yom, J., Kim, T., & Kim, Y. (2018) · Nano Research · doi:10.1007/s12274-018-2101-1 · Cited by 11
Combined impact of alcohol consumption and metabolic syndrome on liver dysfunction in an elderly Chinese population
Zhao, Y., Yuan, X., Lin, T., Yang, Q., Jiang, X., Yang, S. T., & Qiu, Y. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01312-0 · Cited by 13
High-density lipoprotein particles are associated with the risk of mortality from all-causes and cardiovascular diseases (CVDs) in patients with CVD: a systematic review and meta-analysis study
Sharifi‐Zahabi, E., Nasiri, N., Hajizadeh‐Sharafabad, F., Mohammadi, S., Shahbazi, S., & Salehi, N. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02620-8 · Cited by 10
Mass spectrometry meets the challenge of understanding the complexity of the lipoproteome: recent findings regarding proteins involved in dyslipidemia and cardiovascular disease
Singh, S. A., Miyosawa, K., & Aikawa, M. (2015) · Expert Review of Proteomics · doi:10.1586/14789450.2015.1078731 · Cited by 10
Lutein nanodisks protect human retinal pigment epithelial cells from UV light-induced damage
Moschetti, A., Fox, C. A., McGowen, S., & Ryan, R. O. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2022.955022 · Cited by 10
Early time‐restricted feeding improves high‐density lipoprotein amount and function in nonhuman primates, without effects on body composition
Kavanagh, K., Bashore, A. C., Davis, M. A., Jorgensen, M. J., McLouth, C. J., Beavers, D. P., & Parks, J. S. (2022) · Obesity · doi:10.1002/oby.23564 · Cited by 9
Sex-biased and sex hormone-dependent regulation of apolipoprotein A1
Angelov, A., Connelly, P. J., Delles, C., & Kararigas, G. (2023) · Current Opinion in Physiology · doi:10.1016/j.cophys.2023.100654 · Cited by 10
Asthmatic patients with high serum amyloid A have proinflammatory HDL: Implications for augmented systemic and airway inflammation
Yao, X., Kaler, M. M., Qu, X., Kalidhindi, R. S. R., Sviridov, D. O., Dasseux, A., Barr, E. W., Keeran, K. J., Jeffries, K. R., Yu, Z., et al. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.11.917 · Cited by 10
Analysis of “On/Off” Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics
Lu, J. J.-Q., Cleary, Y., Maugeais, C., Weber, C. K., & Mazer, N. A. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.27 · Cited by 10
High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes
Androulakis, E. S., Zacharia, E. M., Παπαγεωργίου, Ν., Lioudaki, E., Bertsias, D., Charakida, M., Siasos, G., & Tousoulis, D. (2017) · Current Cardiology Reviews · doi:10.2174/1573403x13666170209145622 · Cited by 10
Novel findings in relation to multiple anti‐atherosclerotic effects of XueZhiKang in humans
Xu, R., Zhang, Y., Guo, Y., Ma, C., Yao, Y., Li, S., Li, X., Qing, P., Gao, Y., Wu, N., et al. (2017) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2017.09.004 · Cited by 10
Lipidomics of Plasma High-Density Lipoprotein: Insights into Anti-Atherogenic Function
Kontush, A., & Lhomme, M. (2015) · Journal of Glycomics & Lipidomics · doi:10.4172/2153-0637.1000133 · Cited by 10
Self-citation
Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback
Yang, Z., Cao, Y., Hao, D., Yuan, X., Zhang, L., & Zhang, S. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1363661 · Cited by 10
Relation of oxidized-low-density lipoprotein and high-density lipoprotein subfractions in non-treated patients with coronary artery disease
Zhao, X., Zhang, H., Sun, D., Xu, R., Guo, Y., Sun, J., Zhu, C., Wu, N., Zhang, Y., Li, S., et al. (2019) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2019.106345 · Cited by 10
Role of lipoprotein structure and dynamics in disease development
M., Y. Y. C. (2023) · doi:10.24834/isbn.9789178773978 · Cited by 9
High-density lipoprotein-based drug discovery for treatment of atherosclerosis
Du, Y., Wang, L., & Hong, B. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1051963 · Cited by 9
Immature Circulating SP-B, Bound to HDL, Represents an Early Sign of Smoke-Induced Pathophysiological Alterations
Banfi, C., Brioschi, M., Mapelli, M., Gianazza, E., Mallia, A., Zoanni, B., Salvioni, E., Gugliandolo, P., Capra, N., Veglia, F., et al. (2021) · Biomolecules · doi:10.3390/biom11040551 · Cited by 9
Loss-of-function mutation in Pcsk1 increases serum APOA1 level and LCAT activity in mice
Khan, A. A., Kim, N., Korstanje, R., & Choi, S. (2022) · Laboratory Animal Research · doi:10.1186/s42826-021-00111-2 · Cited by 8
Revisiting “Good” and “Bad” Cholesterol. The Battle over Flow through Arteries Now Shifts to Flow through Airways
Fessler, M. B. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201502-0413ed · Cited by 8
Effects of Disease-Causing Mutations on the Conformation of Human Apolipoprotein A-I in Model Lipoproteins
Wilson, C. J., Das, M., Jayaraman, S., Gursky, O., & Engen, J. R. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00538 · Cited by 8
Sphingosine 1-Phosphate and Apolipoprotein M Levels and Their Correlations with Inflammatory Biomarkers in Patients with Untreated Familial Hypercholesterolemia
Juhász, L., Lőrincz, H., Szentpéteri, A., Nádró, B., Varga, É., Paragh, G., & Harangi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214065 · Cited by 8
Reconfigurable Peptide Analogs of Apolipoprotein A-I Reveal Tunable Features of Nanodisc Assembly
Xu, D., Chen, X., Li, Y., Chen, Z., Xu, W., Wang, X., Lv, Y., Wang, Z., Wu, M., Liu, G., et al. (2023) · Langmuir · doi:10.1021/acs.langmuir.2c03082 · Cited by 8
Antilipidemic Drug Therapy Today and in the Future
Kramer, W. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_15 · Cited by 8
Large‐Scale Screening of Natural Products Transactivating Peroxisome Proliferator‐Activated Receptor α Identifies 9S‐Hydroxy‐10E,12Z,15Z‐Octadecatrienoic Acid and Cymarin as Potential Compounds Capable of Increasing Apolipoprotein A‐I Transcription in Human Liver Cells
van der Krieken, S. E., Popeijus, H. E., Bendik, I., Böhlendorf, B., Konings, M. C. J. M., Tayyeb, J. Z., Mensink, R. P., & Plat, J. (2018) · Lipids · doi:10.1002/lipd.12116 · Cited by 8
Utility of high density lipoprotein particle concentration in predicting future major adverse cardiovascular events among patients undergoing angiography
May, H. T., Anderson, J. L., Winegar, D. A., Rollo, J. S., Connelly, M. A., Otvos, J. D., & Muhlestein, J. B. (2016) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2016.09.004 · Cited by 7
The value of HDL subfractions in predicting cardiovascular outcomes in untreated, diabetic patients with stable coronary artery disease: An age- and gender-matched case-control study
Zhang, W., Jin, J., Zhang, H., Zhu, Y., Dong, Q., Sun, J., Guo, Y., Dou, K., Xu, R., & Li, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1041555 · Cited by 7
Ageing, Metabolic Dysfunction, and the Therapeutic Role of Antioxidants
Santos, A. L., & Sinha, S. (2023) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-26576-1_15 · Cited by 8
Sports and HDL-Quality Reflected By Serum Amyloid A and Surfactant Protein B
Sponder, M., Kopecky, C., Campean, I., Emich, M., Fritzer‐Szekeres, M., Litschauer, B., Graf, S., Säemann, M. D., & Strametz‐Juranek, J. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.20388 · Cited by 8
Biomarkers in drug development
Schuck, R. N., Delfino, J. G., Leptak, C., & Wagner, J. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00029-x · Cited by 7
Low-carbohydrate diets increase LDL-cholesterol, and thereby indicate increased risk of CVD
Mansoor, N., Vinknes, K. J., Veierød, M. B., & Retterstøl, K. (2016) · British Journal Of Nutrition · doi:10.1017/s0007114516001343 · Cited by 8
Identification of HeLa cell proteins that interact with Chlamydia�trachomatis glycogen synthase using yeast two‑hybrid assays
Sun, Z., Sun, Y., Li, Y., Luan, X., Chen, H., Wu, H., Peng, B., & Lu, C. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10947 · Cited by 6
Structural Basis and Functional Mechanism of Lipoprotein in Cholesterol Transport
Yang, Z., Hao, D., Che, Y., Zhang, L., & Zhang, S. (2018) · InTech eBooks · doi:10.5772/intechopen.76015 · Cited by 6
Structures of apolipoprotein A-I in high density lipoprotein generated by electron microscopy and biased simulations
Zhu, L., Petrlová, J., Gysbers, P., Hebert, H., Wallin, S., Jegerschöld, C., & Lagerstedt, J. O. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.07.017 · Cited by 6
Association of alpha-aminoadipic acid (2-AAA) with cardiometabolic risk factors in healthy and high-risk individualsPreprint
Desine, S., Gabriel, C. L., Smith, H., Antonetti, O. R., Wang, C., Calcutt, M. W., Doran, A. C., Silver, H. J., Nair, S., Terry, J. G., et al. (2023) · medRxiv · doi:10.1101/2023.06.05.23290990 · Cited by 6
Synergistic Anti-Inflammatory Activity of Lipid-Free Apolipoprotein (apo) A-I and CIGB-258 in Acute-Phase Zebrafish via Stabilization of the apoA-I Structure to Enhance Anti-Glycation and Antioxidant Activities
Cho, K., Bahuguna, A., Lee, Y., Lee, S. H., Domínguez-Horta, M. D. C., & Martínez‐Donato, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105560 · Cited by 7
Pharmacokinetic Properties of Nanomaterials
Nishikawa, M. (2015) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3121-7_12 · Cited by 5
β3-Adrenoceptor activation upregulates apolipoprotein A-I expression in HepG2 cells, which might further promote cholesterol efflux from macrophage foam cells
Gao, X.-Q., Li, Y., & Jiang, Z. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s130088 · Cited by 6
Mathematical Modelling of Material Transfer to High-Density Lipoprotein (HDL) upon Triglyceride Lipolysis by Lipoprotein Lipase: Relevance to Cardioprotective Role of HDL
Schekatolina, S., Lahovska, V., Bekshaev, A. Y., Контуш, С. М., Goff, W. L., & Kontush, A. (2022) · Metabolites · doi:10.3390/metabo12070623 · Cited by 5
Self-citation
Effects of vinegar consumption on cardiometabolic risk factors: A systematic review and meta-analysis of randomized controlled trials
Sohouli, M. H., Kutbi, E., Masri, M. K. A., Dadhkhah, H., Fatahi, S., Santos, H. O., Hekmatdoost, A., & Abu‐Zaid, A. (2022) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2022.102176 · Cited by 5
Phospholipid transfer to high-density lipoprotein (HDL) upon triglyceride lipolysis is directly correlated with HDL-cholesterol levels and is not associated with cardiovascular risk
Ma, F., Darabi, M., Lhomme, M., Tubeuf, E., Canicio, A., Brerault, J., Medadje, N., Rached, F. H., Lebreton, S., Frisdal, É., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.002 · Cited by 5
Self-citation
C/EBP‐β Is Differentially Affected by PPARα Agonists Fenofibric Acid and GW7647, But Does Not Change Apolipoprotein A‐I Production During ER‐Stress and Inflammation
van der Krieken, S. E., Popeijus, H. E., Konings, M. C. J. M., Dullens, S. P. J., Mensink, R. P., & Plat, J. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25731 · Cited by 5
Lipids and Lipoproteins in Alzheimer’s Disease
Stukas, S. K., Kulić, I., Zareyan, S., & Wellington, C. L. (2015) · InTech eBooks · doi:10.5772/59808 · Cited by 5
Perilipin2/adipophilin and ApoA-1 team up to combat atherosclerosis
Pourcet, B., & Staels, B. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv276 · Cited by 5
Lipid exchange of apolipoprotein A‐I amyloidogenic variants in reconstituted high‐density lipoprotein with artificial membranes
Correa, Y., Ravel, M., Imbert, M., Waldie, S., Clifton, L. A., Terry, A. E., Roosen‐Runge, F., Lagerstedt, J. O., Moir, M., Darwish, T. A., et al. (2024) · Protein Science · doi:10.1002/pro.4987 · Cited by 2
Pleiotropic functions and clinical importance of circulating HDL-PON1 complex
Mahrooz, A. (2024) · Advances in clinical chemistry · doi:10.1016/bs.acc.2024.04.003 · Cited by 4
Functional diversity of high-density lipoproteins: finding the golden mean
Metelskaya, V. A. (2021) · Ateroscleroz · doi:10.52727/2078-256x-2021-17-2-61-71 · Cited by 4
Effects of Hedan Tablet (荷丹片) on lipid profile, proprotein convertase subtilisin/kexin type 9 and high-density lipoprotein subfractions in patients with hyperlipidemia: A primary study
Xu, R., Wu, N., Li, S., Zhang, Y., Li, X.-L., Guo, Y., Zhu, C., Liu, G., Dong, Q., & Li, J. (2015) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-015-2140-3 · Cited by 4
Linear reverse risk of HDL-C levels for predicting cardiovascular disease: it is not that straightforward!
Baliga, R. R., Yang, E. H., & Bossone, E. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa032 · Cited by 4
Prevention and Treatment of Obesity-Related Diseases by Diet and Medicinal Plants
Saad, B., Zaid, H., Shanak, S., & Kadan, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-54102-0_4 · Cited by 4
Better Indigenous Risk stratification for Cardiac Health study (BIRCH) protocol: rationale and design of a cross-sectional and prospective cohort study to identify novel cardiovascular risk indicators in Aboriginal Australian and Torres Strait Islander adults
Rémond, M., Stewart, S., Carrington, M. J., Marwick, T. H., Kingwell, B. A., Meikle, P. J., O’Brien, D., Marshall, N. S., & Maguire, G. P. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0662-7 · Cited by 7
Self-citation
Commentary: Triglycerides or HDL cholesterol in cardiovascular disease—which is the true culprit?
Varbo, A., & Nordestgaard, B. G. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyy292 · Cited by 4
Phosphatidylcholine Chain-Length of Bioinspired Lipoprotein Modulates Interactions with Collagen for Intratumor Delivery in Pancreatic Cancer
Li, G., Zhang, Y., Wang, J., Liang, Y., Zhang, Y., Chi, Y., Sun, C., Hu, Z., Wu, S., Lu, G., et al. (2025) · ACS Nano · doi:10.1021/acsnano.4c18963 · Cited by 3
Stratified analysis of carotid plaque and intima–media thickness as stroke predictors in type 2 diabetes
Fu, H., Wei, X., & Wirtz, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1718199 · Cited by 3
The APOA1-SNCA Axis as a Molecular Bridge Between CKD and Parkinson’s Disease: A Systems Biology Model of Kidney-to-Brain Propagation via Exosomal Pathways
Billur, D., Hanagasi, H. A., Bılgıç, B., & Timirci‐Kahraman, Ö. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104176 · Cited by 3
Casz1 and Znf101/Zfp961 differentially regulate apolipoproteins A1 and B, alter plasma lipoproteins, and reduce atherosclerosis
Ansari, A., Yadav, P. K., Zhou, L., Prakash, B., Ijaz, L., Christiano, A., Ahmad, S., Rimbert, A., & Hussain, M. M. (2025) · JCI Insight · doi:10.1172/jci.insight.182260 · Cited by 3
Impaired response of memory Treg to high density lipoproteins is associated with intermediate/high cardiovascular disease risk in persons with HIV
Atehortúa, L., Baig, M., Morris, J. C., Trentman, S., Davidson, W. S., Fichtenbaum, C. J., & Chougnet, C. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1146624 · Cited by 3
Emerging Nanomaterials in Drug Delivery and Therapy
Nargis, M. (2022) · Materials research foundations · doi:10.21741/9781644902172-6 · Cited by 2
High-Density Lipoprotein – A Hero, a Mirage, or a Witness?
Sviridov, D. (2014) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2014.00009 · Cited by 3
Paraoxonase 1 and Its Clinical Relevance
Gugliucci, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00009-4 · Cited by 4
Atherosclerosis
Mayer, F., & Binder, C. J. (2019) · Learning materials in biosciences · doi:10.1007/978-3-030-12270-6_10 · Cited by 3
Scavenger Hunt: SR-B1, Adrenal Insufficiency, IL-17A, and Neutrophilic Airway Inflammation in Asthma
Yao, X., & Levine, S. J. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2021-0089ed · Cited by 3
MicroRNA-541-3p alters lipoproteins to reduce atherosclerosis by degrading Znf101 and Casz1 transcription factorsPreprint
Ansari, A., Yadav, P. K., Zhou, L., Prakash, B., Gangula, B., Ijaz, L., Christiano, A., Ahmad, S., Rimbert, A., & Hussain, M. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.01.565110 · Cited by 3
Dissecting the Structural Dynamics of Authentic Cholesteryl Ester Transfer Protein for the Discovery of Potential Lead Compounds: A Theoretical Study
Zhao, Y., Hao, D., Zhao, Y., Zhang, S., Zhang, L., & Yang, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512252 · Cited by 2
Patterns and Factors Associated with Dyslipidemia Among Patients with Diabetes Mellitus Attending Hoima Regional Referral Hospital, Uganda
Hirsi, A. M., Abdi, A. A., Peris, A., Amandua, J., Muhammad, P., Nur, I. A., Mohamud, M., Hussein, M., Qaws, A., & Jayte, M. (2025) · International Journal of General Medicine · doi:10.2147/ijgm.s494941 · Cited by 2
Effects of fasting on HDL particle function and size distribution
Agus, J., & Zivkovic, A. M. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100859 · Cited by 3
Macrophage-Targeted Nanomedicines
Romero, E. L., Altube, M. J., Perez, A. P., & Morilla, M. J. (2023) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-19-8342-9_10 · Cited by 2
Nuevos tratamientos para la hipercolesterolemia
Pintó, X., & Gómez, M. C. G. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.01.016 · Cited by 2
New agents for hypercholesterolemia
Pintó, X., & Gómez, M. C. G. (2016) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.04.058 · Cited by 2
Lipoprotein in cholesterol transport: Highlights and recent insights into its structural basis and functional mechanism
Chen, S.-Y., Li, N., Jin, T.-L., Gou, L., Hao, D., Tian, Z., Zhang, S., & Zhang, L. (2018) · Chinese Physics B · doi:10.1088/1674-1056/27/2/028702 · Cited by 2
Beyond cholesterol homeostasis: A novel role for PDZK1 in macrophage apoptosis and atherosclerosis
Karunakaran, D. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.012 · Cited by 2
AMPK signaling pathway regulated the expression of the ApoA1 gene via the transcription factor Egr1 during G. parasuis stimulation
He, Y., Peng, Y., Sun, Y., Wan, Y., Zhuo, R., Hu, S., Wang, Y., Hu, X., Jin, H., & Hua, K. (2024) · Veterinary Microbiology · doi:10.1016/j.vetmic.2024.110106 · Cited by 2
Discovery of High-Density Lipoprotein Gene Targets from Classical Genetics to Genome-Wide Association Studies
Freeman, L. A., & Remaley, A. T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-799961-6.00006-8 · Cited by 2
Not so "good" cholesterol
Kritharides, L. (2014) · BMJ · doi:10.1136/bmj.g4664 · Cited by 2
High Density Lipoprotein pathway as a therapeutic target for coronary heart disease: individual participant meta-analysis in 28,597 individuals with 4197 coronary eventsPreprint
Mulick, A. R., Prieto‐Merino, D., Tillin, T., Havulinna, A. S., Shipley, M. J., Valera‐Gran, D., Gentry‐Maharaj, A., Ryan, A., Meena Kumari, B., Jukema, J. W., et al. (2020) · medRxiv · doi:10.1101/2020.03.02.19010173 · Cited by 2
Risk Factors for Cardiovascular Disease
Teufel, E. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99837-5 · Cited by 2
Discovery of (E)-4-styrylphenoxy-propanamide: A dual PPARα/γ partial agonist that regulates high-density lipoprotein-cholesterol levels, modulates adipogenesis, and improves glucose tolerance in diet-induced obese mice
Dutra, L. A., Lacerda, M. G., Inácio, M. D., Martins, J. W. L., Silva, A. C. L., da Silva, P. B., Chorilli, M., Amato, A. A., Baviera, A. M., Passarelli, M., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105600 · Cited by 1
Atherosclerosis
Mayer, F., Innerhofer, R., Köller, T., & Binder, C. J. (2024) · Learning materials in biosciences · doi:10.1007/978-3-031-64591-4_10 · Cited by 1
Regulation of HDL dysfunctionality by phosphatidylethanolamine links poly-unsaturated fatty acids with atherosclerotic cardiovascular diseases
Taradeh, M., Hardy, L. M., Dahik, V. D., Lhomme, M., Wang, H., Reydellet, C., Materne, C., Pukar, K. C., Bun, E., Clemessy, M., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102281 · Cited by 2
Self-citation
Challenges and future directions for Mendelian randomization
Sanderson, E. C. M., Levin, M. G., Walker, V. M., Yuan, S., Badini, I., Dolce, J., Mahida, K. J., Nho, J.-W., Pingault, J., Damrauer, S. M., et al. (2026) · Nature Genetics · doi:10.1038/s41588-026-02546-6 · Cited by 2
Common and distinct genetic features of three atherosclerotic cardiovascular diseases
Li, L., Malik, R., Abrahamian, C., von Scheidt, M., Chen, Z., Kessler, T., Dichgans, M., & Schunkert, H. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120733 · Cited by 2
Biohumoral and comorbidity determinants of low HDL-C during acute phase response in a setting of in-hospital patients
VUONO, S. D., Ricci, M. A., Villa, A., Gentili, A., Scavizzi, M., Ciuffetti, G., Pirro, M., Ferri, C., & Lupattelli, G. (2015) · Clinical Lipidology · doi:10.2217/clp.15.17 · Cited by 1
Pharmaka mit Wirkung auf den Lipidstoffwechsel
Offermanns, S. (2016) · Springer-Lehrbuch · doi:10.1007/978-3-662-46689-6_43 · Cited by 1
Analysis of TEM micrographs with deep learning reveals APOE genotype-specific associations between HDL particle diameter and Alzheimer’s dementia
Zheng, J. J., Hong, B. V., Agus, J., Tang, X., Guo, F., Lebrilla, C. B., Maezawa, I., Jin, L., Vreeland, W. N., Ripple, D. C., et al. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100962 · Cited by 1
Effects of replacing sitting with standing and walking on cholesterol metabolism and inflammation in men and women who are overweight or obese
Zwaan, W., Duvivier, B. M. F. M., Savelberg, H. H. C. M., Popeijus, H. E., Konings, M. C. J. M., Mensink, R. P., & Plat, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119143 · Cited by 1

Authors: Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E.
Affiliations: Baker Heart and Diabetes Institute (AU)
Inserm (FR)
University of Oxford (GB)
Corresponding author: Kingwell, Bronwyn A.
ORCID: Kingwell, Bronwyn A.
Chapman, M. John
Kontush, Anatol
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2014-05-23
Volume: 13
Issue: 6
Pages: 445-464
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd4279
OpenAlex: W1993577107
Cited by: 354
References: 228
Citations by year: 2026: 11 · 2025: 15 · 2024: 9 · 2023: 28 · 2022: 22 · 2021: 21 · 2020: 22 · 2019: 33 · 2018: 33 · 2017: 43 · 2016: 53 · 2015: 51 · 2014: 12
FWCI: 10.00
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: HDL cholesterol, HDL-targeted therapy, HDL particle number, reverse cholesterol transport, atheroprotection, cardiovascular disease, clinical trial failure
MeSH terms: Animals, Hypolipidemic Agents, Cardiovascular Diseases, Clinical Trials as Topic, Humans, Phosphatidylcholine-Sterol O-Acyltransferase, Lipoproteins, HDL, Models, Biological, Niacin, Recombinant Proteins, Drugs, Investigational, Up-Regulation, Apolipoprotein A-I, Cholesterol Ester Transfer Proteins, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HDL-targeted therapies: progress, failures and future

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks